Complete remission of psoriasis following bevacizumab therapy for colon cancer

被引：54

作者：

Akman, A. ^{[1
]}

Yilmaz, E. ^{[1
]}

Mutlu, H. ^{[2
]}

Ozdogan, M. ^{[2
]}

机构：

[1] Sch Med Antalya, Dept Dermatol & Venerol, Antalya, Turkey

[2] Sch Med Antalya, Dept Med Oncol, Antalya, Turkey

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2009年 / 34卷 / 05期

关键词：

ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS; XENOGRAFTS;

D O I：

10.1111/j.1365-2230.2008.02991.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which is used to treat several cancers. Currently, experience with anti-VEGF treatment for psoriasis is limited, and no published reports on this use exist. We describe a patient with metastatic colon cancer and psoriasis who experienced complete remission of psoriasis during treatment with bevacizumab and combination chemotherapy without any other treatment for psoriasis. These data suggest that bevacizumab may be a promising therapeutic agent for the treatment of psoriasis.

引用

页码：E202 / E204

页数：3

共 10 条

[1] Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB [J].

Akman, Ayse ;

Dicle, Ozlem ;

Yilmaz, Fikriye ;

Coskun, Mesut ;

Yilmaz, Ertan .

PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2008, 24 (03) :123-127

[2] Recent advances in cutaneous angiogenesis [J].

Bhushan, M ;

Young, HS ;

Brenchley, PEC ;

Griffiths, CEM .

BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (03) :418-425

[3] OVEREXPRESSION OF VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS IN PSORIASIS [J].

DETMAR, M ;

BROWN, LF ;

CLAFFEY, KP ;

YEE, KT ;

KOCHER, O ;

JACKMAN, RW ;

BERSE, B ;

DVORAK, HF .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (03) :1141-1146

[4] Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts [J].

Kaneko, Setsuko ;

Ishibashi, Makiko ;

Kaneko, Michio .

CANCER SCIENCE, 2008, 99 (06) :1209-1217

[5]

MALHOTRA R, 1989, LAB INVEST, V61, P162

[6] Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts [J].

Ooyama, Akio ;

Oka, Toshinori ;

Zhao, Hong-ye ;

Yamamoto, Masatatsu ;

Akiyama, Shin-ichi ;

Fukushima, Masakazu .

CANCER LETTERS, 2008, 267 (01) :26-36

[7]

Salesi N, 2005, ANTICANCER RES, V25, P3619

[8] Neovastat (Æ-941), an inhibitor of angiogenesis:: Randomized phase I/II clinical trial results in patients with plaque psoriasis [J].

Sauder, DN ;

DeKoven, J ;

Champagne, P ;

Croteau, D ;

Dupont, E .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (04) :535-541

[9] Angiogenesis therapy moves beyond cancer [J].

Wilson, JF .

ANNALS OF INTERNAL MEDICINE, 2004, 141 (02) :165-168

[10] Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis [J].

Young, Helen S. ;

Summers, Angela M. ;

Read, Ian R. ;

Fairhurst, David A. ;

Plant, Darren J. ;

Campalani, Emanuela ;

Smith, Catherine H. ;

Barker, Jonathan N. W. N. ;

Detmar, Michael J. ;

Brenchley, Paul E. C. ;

Griffiths, Christopher E. M. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (02) :453-459

← 1 →